“. We are reiterating our Overweight rating and $135 price target. We believe that early trends from the launch are in line with our expectations. We are staying with Alnylam as a top franchise pick in 2019, and are not worried about launch trends that are really too early to read into in a new market it is building. Not surprising, investors paid the closest attention to the new start number that was 125 patients after about 7 weeks of launch. We think that this number of new starts is solid for hATTR amyloidosis, a disease for which there haven’t been many therapies to treat these patients. We also think that Alnylam has been very clear that this is a market that the new players would have to build.”,” the firm’s analyst commented.
ALNY has been the subject of a number of other reports. Needham & Company LLC reissued a buy rating and issued a $152.00 price target on shares of Alnylam Pharmaceuticals in a research report on Thursday, September 13th. Cowen restated a buy rating and issued a $157.00 price objective on shares of Alnylam Pharmaceuticals in a report on Thursday, August 2nd. ValuEngine downgraded Alnylam Pharmaceuticals from a strong-buy rating to a buy rating in a report on Friday, September 21st. BidaskClub downgraded Alnylam Pharmaceuticals from a hold rating to a sell rating in a report on Thursday, August 2nd. Finally, BMO Capital Markets dropped their price objective on Alnylam Pharmaceuticals from $127.00 to $125.00 and set an outperform rating on the stock in a report on Monday, August 13th. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and fourteen have issued a buy rating to the stock. Alnylam Pharmaceuticals presently has an average rating of Buy and a consensus price target of $142.94.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($2.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.02) by ($0.41). The company had revenue of $2.07 million during the quarter, compared to analysts’ expectations of $22.66 million. Alnylam Pharmaceuticals had a negative return on equity of 38.09% and a negative net margin of 533.52%. Alnylam Pharmaceuticals’s revenue for the quarter was down 87.9% compared to the same quarter last year. During the same period last year, the company earned ($1.34) earnings per share. On average, analysts predict that Alnylam Pharmaceuticals will post -7.28 EPS for the current year.
In related news, COO Yvonne Greenstreet sold 2,500 shares of the stock in a transaction that occurred on Thursday, August 30th. The stock was sold at an average price of $120.00, for a total value of $300,000.00. Following the transaction, the chief operating officer now owns 1,916 shares in the company, valued at $229,920. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 4.30% of the company’s stock.
A number of hedge funds have recently made changes to their positions in ALNY. Nelson Van Denburg & Campbell Wealth Management Group LLC acquired a new position in Alnylam Pharmaceuticals during the second quarter valued at approximately $137,000. Opera Trading Capital acquired a new position in Alnylam Pharmaceuticals during the third quarter valued at approximately $137,000. Mutual of America Capital Management LLC grew its holdings in Alnylam Pharmaceuticals by 98.5% during the second quarter. Mutual of America Capital Management LLC now owns 1,935 shares of the biopharmaceutical company’s stock valued at $191,000 after purchasing an additional 960 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. grew its holdings in Alnylam Pharmaceuticals by 600.9% during the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,278 shares of the biopharmaceutical company’s stock valued at $200,000 after purchasing an additional 1,953 shares during the last quarter. Finally, IPG Investment Advisors LLC acquired a new position in Alnylam Pharmaceuticals during the second quarter valued at approximately $217,000. Institutional investors own 90.37% of the company’s stock.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.
See Also: What is a balanced fund?
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.